Reports of analysis from component suppliers are accepted without establishing the reliability of the supplier's analyses through appropriate validation of the supplier's test results at appropriate intervals.
Inspection Record
Sumitomo Osaka Cement Co., Ltd — FDA 483 Findings
View the regulator's official source The source document is always the basis for judgement.
Findings
Cleaning Validation Program is deficient, Specifically The firm manufactured and shipped 8 ari products for the US market in the past three years each with a different particle size as listed below: Product Name Product Type | == NDC The firm performed three cleaning validations to establish successful product change over cleaning as detailed below for and product changeovers: i a completion A washing amount of or more is required.
Out of Specification investigation (OOS) is deficient and further no CAPA is initiated to prevent recurrence.
Review of audit trail for analytical data generated by your firm is inadequate.
The roles and responsibilities ofthe quality unit is not fully followed.
A record as of the US FDA document published on 2026-11-05. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.